Crispr Therapeutics earnings missed by $0.11, revenue fell short of estimates
Crispr Therapeutics (CRSP) reported Q3 EPS of -$1.15, missing estimates by $0.11, and revenue of $12.67M, below the $14.62M consensus. The stock is down 3.20% over 3 months and 19.38% over 12 months. Analysts revised EPS 12 times positively and 3 times negatively in the last 90 days.
How this was made
The 30-second read
Why it matters
Because both EPS and revenue missed consensus, traders may reassess near-term expectations and risk premium, even without additional guidance details in the text.
Market read
A straightforward earnings miss on EPS and revenue is a tradable catalyst for CRSP, typically driving same-day positioning and volatility.
What to watch
No details are provided on cash position, pipeline milestones, or management commentary, which can dominate the stock’s medium-term direction despite the headline miss.
Background
The piece is an earnings recap for CRISPR Therapeutics’ Q3 results, comparing reported EPS and revenue to analyst consensus.
Ticker impact
CRSP reported Q3 EPS of -1.15, missing the -1.04 estimate, and revenue of $12.67M versus $14.62M consensus.
Likely downward pressure as the market reprices the company’s near-term fundamentals after the miss.
The article provides the quarter’s EPS and revenue versus consensus, which are direct drivers of post-earnings positioning for a single-name biotech.
Market effects
Biotech sentiment may soften modestly if investors interpret the miss as continued commercialization or cost-pressure challenges.
Limited, primarily affects US biotech risk appetite rather than a broad regional move.
Low, as the disclosure is company-specific and not tied to a global regulatory or macro catalyst.
Counterpoint
The article does not mention guidance or balance-sheet deterioration; investors may treat the miss as within expected volatility for CRISPR platform companies.
Key entities
- companyCrispr Therapeutics
NASDAQ-listed gene-editing company reporting Q3 EPS and revenue versus consensus.
